<DOC>
	<DOC>NCT00961441</DOC>
	<brief_summary>To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.</brief_summary>
	<brief_title>Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subjects with a diagnosis of epilepsy on up to three concomitant antiepileptic drugs Subjects on levetiracetam immediate release (IR) can be enrolled if on a stable dose for 7 days Subjects with a history of status epilepticus within 3 months of Visit 1 Subject has difficult venous accessibility</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Children</keyword>
	<keyword>Adults</keyword>
</DOC>